India's Breast Cancer Drug Market Will Almost Doub...( Indian Physicians Start to Incorporat...),Health

Indian Physicians Start to Incorporate Targeted Therapies to Achieve Better Efficacy and Toxicity Profiles Than Conventional Therapies, According to a Report From Decision Resources

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian breast cancer drug market will almost double from $35 million in 2007 to $64 million by 2012. According to the new Emerging Markets report entitled Breast Cancer in India, this growth will be fueled by rising disease prevalence, increasing wealth and growing disease awareness.

The report finds that docetaxel (Sanofi-Aventis's Taxotere, Indian products) and epirubicin (Pfizer's Farmorubicin, Indian products) will continue to be the market leaders, but sales of trastuzumab and bevacizumab (Roche's Herceptin and Avastin), gemcitabine (Eli Lilly's Gemcite, Indian products), and capecitabine (Roche's Xeloda, Indian products) will grow rapidly during this period.

The report also finds that Indian physicians in the six surveyed regions (Delhi, Mumbai, Bangalore, Chennai, Jaipur and Lucknow) are encouraged by the success of targeted therapies in other major markets and have started to increasingly incorporate targeted therapies --- Herceptin, Avastin, GlaxoSmithKline's Tykerb --- into breast cancer treatment to achieve better efficacy and toxicity profiles than conventional therapies. However, premium prices are the major constraint for market uptake.

"India's fast-growing economy will drive demand for novel therapies with higher efficacy and fewer side effects, which usually command high prices, among the burgeoning middle class and higher-income breast cancer patients," added Jing Wu, analyst at Decision Resources.

EMERGING MARKETS REPORTS

The Ultimate Analysis of Ph
'/>"/>